| Cat.No. | Name | Information |
|---|---|---|
| M8975 | CWHM-12 | CWHM-12 is a potent inhibitor of αV integrins with IC50 values of 0.2, 0.8, 1.5, and 1.8 nM for αvβ8, αvβ3, αvβ6, and αvβ1, respectively. |
| M9173 | Cilengitide TFA | Cilengitide TFA is a potent integrin inhibitor for αvβ3 and αvβ5 receptor with IC50 of 4.1 nM, 79 nM in cell-free assays respectively. |
| M2042 | Cilengitide | Cilengitide (EMD 121974, NSC 707544) is a selective inhibitor of αvβ3 integrin and αvβ5 integrin with IC50 of 1 nM and 140 nM, respectively. |
| M13754 | OSU-T315 | OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain). |
| M13752 | BIO-1211 | BIO-1211 is a highly selective and orally active α4β1 (VLA-4) inhibitor, with IC50 values of 4 nM and 2 μM for α4β1 and α4β7, respectively. |
| M10730 | GRGDSP TFA | GRGDSP (TFA) is an integrin inhibitor. |
| M10729 | TR-14035 | TR-14035 is an orally active α4b7/a4b1 integrins (a4b7/a4b1 integrindual inhibitors, for α4b7 和 a4b1 function IC50 The values are 7 nM and 87 nM, respectively. TR-14035 can be used for the study of inflammatory and autoimmune diseases. |
| M10728 | Cyclo(RGDyK) trifluoroacetate | Cyclo(RGDyK) trifluoroacetate is an effective selectivity αVβ3 integrin inhibitors,IC50 20 nM. |
| M10636 | Echistatin TFA | Echistatin TFA is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1. |
| M10557 | RGD peptide (GRGDNP) (TFA) | RGD peptide TFA acts as an inhibitor of integrin-ligand interactions and plays an important role in cell adhesion, migration, growth, and differentiation. |
| M10480 | Tetraiodothyroacetic acid | Tetraiodothyroacetic acid (tetrac) is a thyrointegrin receptor antagonist. Tetraiodothyroacetic acid blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. |
| M10211 | Obtustatin | Obtustatin is a potent integrin α1β1 inhibitor with IC50 of 0.8 nM for α1β1 binding to type IV collagen. |
| M10209 | Cyclo(-RGDfK) | Cyclo (-RGDfK) is an effective and specific αvβ3 integrin inhibitor. |
| M9781 | E7820 | E7820 is a α2 integrin inhibitor which suppressing integrin alpha 2, a cell adhesion molecule expressed on endothelial cells. |
| M8939 | Firategrast | Firategrast (SB-683699) is an orally bioavailable alpha4 beta1/alpha4 beta7 integrin antagonist. |
| M7384 | TCS 2314 | TCS 2314 is a α 4β 1 (VLA-4) antagonist. |
| M6905 | Leukadherin-1 | Leukadherin-1 is a allosteric activator of CD11b/CD18. Leukadherin-1 increases CD11b/CD18-dependent cell adhesion to fibrinogen with an EC50 of 4 μM. |
| M6538 | BTT 3033 | BTT 3033 is a selective inhibitor of integrin α 2β 1. |
| M6363 | A-286982 | A-286982 is a potent inhibitor of the LFA-1/ICAM-1 interaction. A-286982 binds to the I domain allosteric site (IDAS). |
| M6018 | Tirofiban hydrochloride monohydrate | Tirofiban hydrochloride monohydrate is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonist |
| M5852 | Lifitegrast | Lifitegrast is an antagonist of integrin lymphocyte function associated antigen-1 (LFA-1). The IC50 of Jurkat T cells to icAM-1 was 2.98nM. Lifitegrast blocks the interaction between LFA-1 and ICAM-1, thereby reducing T cell activity and cytokine secretion. |
| M5619 | Eptifibatide | Eptifibatide is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class. |
| M5241 | GLPG0187 | GLPG0187 inhibited the progression of bone metastasis. Maximum efficacy of inhibition of bone metastasis was achieved when GLPG0187 was combined with the standard-of-care metastatic breast cancer treatments. |
| M3789 | ATN-161 TFA | ATN-161 TFA salt is a novel small peptide inhibitor of integrin α5β1; a beta integrin antagonist with antitumor activity. |
| M3074 | Tirofiban | Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
